ALK and non-small cell lung carcinoma: Given the advanced clinical stage (IIIB-N3) of the patient and the lack of established neoadjuvant treatment regimens or drug selection for novel ALK-rearranged NSCLC, the multidisciplinary team (MDT) at our institution opted for neoadjuvant alectinib, which has demonstrated superior efficacy over crizotinib in advanced ALK-rearranged disease (Camidge et al., 2019).